Comparison of silver sulphadiazine and Suprasorb A+AgTM in the treatment of partial thickness burn wounds
PDF
Cite
Share
Request
Original Article
VOLUME: 28 ISSUE: 4
P: 189 - 192
December 2012

Comparison of silver sulphadiazine and Suprasorb A+AgTM in the treatment of partial thickness burn wounds

Turk J Surg 2012;28(4):189-192
1. Konya Eğitim ve Araştırma Hastanesi, Genel Cerrahi Kliniği, Konya, Türkiye
No information available.
No information available
PDF
Cite
Share
Request

Abstract

Purpose: The ideal treatment agent for partial thickness burn wound therapy is obscure at the moment. In the present study we aimed to compare silver sulphadiazine and Suprasorb A+AgTM in the treatment of partial thickness burn wounds. Materials and Methods: This study included 48 patients admitted to the Konya Education and Research Hospital Burn Unit and treated for partial thickness burns in 2009 and 2010. Twenty five patients treated with silver sulphadiazine and 23 patients with suprasorb A+AgTM. Patients' their gender, age, etiology of burn, percent of total body surface area, 80% and full epitelisation time, length of hospital stay, the end of treatment satisfaction of patients and recommendation to other patients are compared. Results: Between the two groups, there was no difference in gender, age, total body surface area and etiology of burn. Also there was no difference in 80% epithelialization and full epithelialization days. Length of hospital stay was longer in the silver sulphadiazine group. In the Suprasorb A+AgTM group, satisfaction of patients and recommendation of the same treatment for other patients were higher significant statistically. Conclusion: It is seen that Suprasorb A+AgTM is a treatment method which can be preferred in partial thickness burn treatment because of shortness of duration of stay in hospital, no need for changing dressings frequently and satisfaction of patients.

Keywords:
Partial thickness burn wounds, silver sulphadiazine, Suprasorb A+AgTM

References

1
Papini RP, Wilson AP, Steer JA, et al. Wound management in burn centres in the United Kingdom. Br J Surg 1995; 82: 505-509. http://dx.doi.org/10.1002/ bjs.1800820423 [CrossRef]
2
Bragg PD, Rainnie DJ. The effect of silver ions on the respiratory chain of Escherichia coli. Can J Microbiol 1974; 20: 883-889. http://dx.doi.org/10.1139/ m74-135 [CrossRef]
3
Feng QL, Wu J, Chen GQ, et al. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res 2000; 52: 662-668. http://dx.doi.org/
4
1002/1097-4636(20001215)52:4<662::A ID-JBM10>3.0.CO;2-3 [CrossRef]
5
Holt KB, Bard AJ. Interaction of silver( I) ions with the respiratory chain of Escherichia coli: an electrochemical and scanning electrochemical microscopy study of the antimicrobial mechanism of micromolar Ag+. Biochemistry 2005; 44: 13214-13223. http://dx.doi.org/10.1021/ bi0508542 [CrossRef]
6
Warriner R, Burrell R. Infection and the chronic wound: a focus on silver. Adv Skin Wound Care 2005; 18: 2-12. http://dx.doi.org/10.1097/00129334- 200510001-00001 [CrossRef]
7
Atiyeh BS, Costagliola M, Hayek SN, et al. Effect of silver on burn wound infection control and healing: review of the literature. Burns 2007; 33: 139-148. http:// dx.doi.org/10.1016/j.burns.2006.06.010 [CrossRef]
8
Wright JB, Lam K, Buret AG, et al. Early healing events in a porcine model of contaminated wounds: effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair Regen 2002; 10: 141-151. http://dx.doi.org/10.1046/j.1524- 475X.2002.10308.x [CrossRef]
9
Demling RH, DeSanti L. The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns 2002; 28: 264. http://dx.doi. org/10.1016/S0305-4179(01)00119-X [CrossRef]
10
Lansdown AB. Silver. 2: Toxicity in mammals and how its products aid wound repair. J Wound Care 2002; 11: 173-177.
11
Cho Lee AR, Leem H, Lee J, et al. Reversal of silver sulfadiazine-impaired wound healing by epidermal growth factor. Biomaterials 2005; 26: 4670-4676. http://dx.doi.org/10.1016/j.biomaterials. 2004.11.041 [CrossRef]
12
Poon VK, Burd A. In vitro cytotoxity of silver: implication for clinical wound care. Burns 2004; 30: 140-147. http:// dx.doi.org/10.1016/j.burns.2003.09.030 [CrossRef]
13
Hollinger MA. Toxicological aspects of topical silver pharmaceuticals. Crit Rev Toxicol 1996; 26: 255-260. http:// dx.doi.org/10.3109/10408449609012524 [CrossRef]
14
Sawhney CP, Sharma RK, Rao KR, et al. Long-term experience with 1 percent topical silver sulphadiazine cream in the management of burn wounds. Burns 1989; 15: 403-406. http://dx.doi. org/10.1016/0305-4179(89)90110-1 [CrossRef]
15
Maghsoudi H, Monshizadeh S, Mesgari M. A comparative study of the burn wound healing properties of saline- soaked dressing and silver sulfadiazine in rats. Indian J Surg 2011; 7: 24-
16
http://dx.doi.org/10.1007/s12262- 010-0169-2 [CrossRef]
17
Klasen HJ. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns 2000; 26: 131-138. http://dx.doi.org/10.1016/ S0305-4179(99)00116-3 [CrossRef]
18
Chaby G, Viseux V, Poulain JF, et al. Topical silver sulfadiazine- induced acute renal failure. Ann Dermatol Venereol 2005; 132: 891-893. http://dx. doi.org/10.1016/S0151-9638(05)79509-0 [CrossRef]
19
Choban PS, Marshall WJ. Leukopenia secondary to silver sulfadiazine: frequency, characteristics and clinical consequences. Am Surg 1987; 53: 515-517.
20
Wiegand C, Heinze T, Hipler UC. Comparative in vitro study on cytotoxicity, antimicrobial activity, and binding capacity for pathophysiological factors in chronic wounds of alginate and silver- containing alginate. Wound Repair Regen. 2009; 17: 511-521. http://dx.doi. org/10.1111/j.1524-475X.2009.00503.x [CrossRef]
21
Sheridan RL, Petras L, Lydon M, et al. Once-daily wound cleansing and dressing change: efficacy and cost. J Burn Care Rehabil 1997; 18: 139-140. http://dx.doi. org/10.1097/00004630-199703000-00008 [CrossRef]
22
Dickinson SJ. Topical therapy of burns in children with silver sulfadiazine. N Y State J Med 1973; 73: 2045-2049.